A Phase II Randomized Controlled Trial of Renshen Yangrong Tang Herbal Extract Granules for Fatigue Reduction in Cancer Survivors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Phase II Randomized Controlled Trial of Renshen Yangrong Tang Herbal Extract Granules for Fatigue Reduction in Cancer Survivors

Published:2020-05 Issue:5 Volume:59 Page:966-973
ISSN:0885-3924
Container-title:Journal of Pain and Symptom Management
language:en
Short-container-title:Journal of Pain and Symptom Management

Author:

Xu Yichen,Wang Xin Shelley,Chen Yanzhi,Shi Qiuling,Chen Tsun Hsuan,Li Pingping

Funder

Key Program Foundation of Beijing Administration

Publisher

Elsevier BV

Subject

Anesthesiology and Pain Medicine,Neurology (clinical),General Nursing

Reference34 articles.

1. ASCPRO recommendations for the assessment of fatigue as an outcome in clinical trials;Barsevick;J Pain Symptom Manage,2010

2. Symptom burden in cancer survivors 1 year after diagnosis: a report from the American Cancer Society's studies of cancer survivors;Shi;Cancer,2011

3. Prevalence and characteristics of moderate-to-severe fatigue: a multicenter study in cancer patients and survivors;Wang;Cancer,2014

4. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis;Mustian;JAMA Oncol,2017

5. Pharmacologic interventions for fatigue in cancer and transplantation: a meta-analysis;Tomlinson;Curr Oncol,2018

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Renshen Yangrong decoction for secondary malaise and fatigue: network pharmacology and Mendelian randomization study;Frontiers in Nutrition;2024-06-20

2. Real-world Chinese herbal medicine for Parkinson's disease: a hospital-based retrospective analysis of electronic medical records;Frontiers in Aging Neuroscience;2024-05-02

3. The Effectiveness of Traditional Chinese Medicine in Treating Malignancies via Regulatory Cell Death Pathways and the Tumor Immune Microenvironment: A Review of Recent Advances;The American Journal of Chinese Medicine;2024-01

4. Ferroptosis: A New Research Direction of Artemisinin and Its Derivatives in Anti-Cancer Treatment;The American Journal of Chinese Medicine;2024-01

5. A Report of Two Cases of the Use of Korean Medicine Treatment of Patients with Post-COVID-19 Conditions;The Journal of Internal Korean Medicine;2023-10-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3